KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
Université de Versailles Saint-Quentin-en-Yvelines · Université Paris Cité · +1 more institution
Abstract
PURPOSE: Cetuximab is efficient in advanced colorectal cancer (CRC). We previously showed that KRAS mutations were associated with resistance to cetuximab in 30 CRC patients. The aim of this study was to validate, in an independent larger series of 89 patients, the prognostic value of KRAS mutations on response to cetuximab and survival. PATIENTS AND METHODS: Eighty-nine metastatic CRC patients treated with cetuximab after treatment failure with irinotecan-based chemotherapy were analyzed for KRAS mutation by allelic discrimination on tumor DNA. The association between KRAS mutations and tumor response, skin toxicity, progression-free survival (PFS) and overall survival (OS) was analyzed. RESULTS: A KRAS…
Citation impact
- FWCI
- 94.38
- Percentile
- 100%
- References
- 23
Authors
19- ALAstrid LièvreCorresponding
Université de Versailles Saint-Quentin-en-Yvelines, Université Paris Cité, Assistance Publique – Hôpitaux de Paris
- JBJean‐Baptiste Bachet
Université de Versailles Saint-Quentin-en-Yvelines, Université Paris Cité, Assistance Publique – Hôpitaux de Paris
- VBValérie Boige
Université de Versailles Saint-Quentin-en-Yvelines, Université Paris Cité, Assistance Publique – Hôpitaux de Paris
- ACAnne Cayre
Université de Versailles Saint-Quentin-en-Yvelines, Université Paris Cité, Assistance Publique – Hôpitaux de Paris
- DLDelphine Le Corre
Université de Versailles Saint-Quentin-en-Yvelines, Université Paris Cité, Assistance Publique – Hôpitaux de Paris
Topics & keywords
- Cetuximab
- KRAS
- Medicine
- Colorectal cancer
- Internal medicine
- Irinotecan
- Oncology
- Chemotherapy